Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: The final analysis of cohort 1.

被引：0
作者：
Seedor, Rino S.
Orloff, Marlana M.
Sharpe-Mills, Erin
Hulse, Liam
Shelat, Reshma
Shimada, Ayako
Chervoneva, Inna
Shields, Carol L.
Shields, Jerry A.
Mastrangelo, Michael J.
Sato, Takami
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA
[2] Wills Eye Hosp & Res Inst, Oncol Serv, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9586
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
    Mocellin, Simone
    Pasquali, Sandro
    Rossi, Carlo R.
    Nitti, Donato
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (07): : 493 - 501
  • [42] A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.
    Si, Lu
    Wang, Xuan
    Kong, Yan
    Lian, Bin
    Chi, Zhi Hong
    Cui, Chuan Liang
    Sheng, Xi Nan
    Mao, Li Li
    Tang, Bi Xia
    Li, Si Ming
    Yan, Qiao Xie
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer A Phase II Study
    Bajetta, Emilio
    Pietrantonio, Filippo
    Buzzoni, Roberto
    Ferrario, Erminia
    Valvo, Francesca
    Mariani, Luigi
    Dotti, Katia F.
    Biondani, Pamela
    Formisano, Barbara
    Gevorgyan, Arpine
    Grassi, Paolo
    Di Bartolomeo, Maria
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (06): : 545 - 549
  • [44] Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
    Sabado, Rachel Lubong
    Pavlick, Anna
    Gnjatic, Sacha
    Cruz, Crystal M.
    Vengco, Isabelita
    Hasan, Farah
    Spadaccia, Meredith
    Darvishian, Farbod
    Chiriboga, Luis
    Holman, Rose Marie
    Escalon, Juliet
    Muren, Caroline
    Escano, Crystal
    Yepes, Ethel
    Sharpe, Dunbar
    Vasilakos, John P.
    Rolnitzsky, Linda
    Goldberg, Judith D.
    Mandeli, John
    Adams, Sylvia
    Jungbluth, Achim
    Pan, Linda
    Venhaus, Ralph
    Ott, Patrick A.
    Bhardwaj, Nina
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (03) : 278 - 287
  • [45] First interim analysis of the SirTac trial: A randomized phase II study of SIRT and DSMTACE in patients with liver metastases from uveal melanoma.
    Peuker, Caroline-Anna Anna
    De Bucourt, Maximilian
    Gebauer, Bernhard
    Amthauer, Holger
    Erxleben, Christoph
    Eucker, Jan
    Keller, Ulrich
    Leyvraz, Serge
    Joussen, Antonia M.
    Keilholz, Ulrich
    Ochsenreither, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
    Zhang, Yi
    Zhou, Hu
    Suo, Shanshan
    Zhuang, Junling
    Yang, Linhua
    He, Aili
    Liu, Qingchi
    Du, Xin
    Gao, Sujun
    Li, Yarong
    Li, Yan
    Chen, Yuqing
    Wu, Wen
    Zhu, Huanling
    He, Guangsheng
    Hong, Mei
    Jiang, Qian
    Jiang, Zhongxing
    Jing, Hongmei
    Wang, Jishi
    Xu, Na
    Yue, Lingling
    Zheng, Cuiping
    Zhou, Zeping
    Jin, Chenghao
    Li, Xin
    Liu, Lin
    Xu, Yajing
    Wu, Dengshu
    Zhang, Feng
    Zhang, Jin
    Wu, Liqing
    Yin, Hewen
    Lv, Binhua
    Xiao, Zhijian
    Jin, Jie
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [47] Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
    Luke, Jason J.
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Eggermont, Alexander M. M.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina V.
    Mohr, Peter
    Robert, Caroline
    Gershenwald, Jeffrey E.
    Poklepovic, Andrew Stewart
    Ross, Merrick I.
    Scolyer, Richard A.
    Yoon, Charles
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Sondak, Vernon K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [48] A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Profile: Final Results of the Valena Trial
    Kuendgen, Andrea
    Luebert, Michael
    Schlenk, Richard F.
    Platzbecker, Uwe
    Haase, Detlef
    Haferlach, Torsten
    Schnittger, Susanne
    Giagounidis, Aristoteles
    Brings, Carolin
    Germing, Ulrich
    Haas, Rainer
    Gattermann, Norbert
    BLOOD, 2014, 124 (21)
  • [49] Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes
    Raza, A
    Lisak, L
    Billmeier, J
    Pervaiz, H
    Mumtaz, M
    Gohar, S
    Wahid, K
    Galili, N
    LEUKEMIA & LYMPHOMA, 2006, 47 (03) : 433 - 440
  • [50] Adjuvant fermented wheat germ extract (Avemar™) nutraceutical improves survival of high-risk skin melanoma patients:: A randomized, pilot, phase II clinical study with a 7-year follow-up
    Demidov, Lev V.
    Manziuk, Ljudmila V.
    Kharkevitch, Galina Y.
    Pirogova, Nina A.
    Artamonova, Elena V.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 477 - 482
12345